Which concept is best captured by the statement: The critical path dimension for assessing safety emphasizes showing the product is safe for each stage of development?

• A. Show the product is safe for each stage of development
• B. Prove safety only in animal studies
• C. Wait for post-market surveillance
• D. Immediate market approval without trials

Answer: (A)

The main idea is that safety needs to be demonstrated at each stage of development, not just in one part of the process. This approach treats safety as an ongoing, stage-by-stage requirement: thorough preclinical evaluations to anticipate risks, cautious progression through early human trials with close safety monitoring, and adequate demonstration of safety in larger trials before moving toward the market. By showing the product is safe for every development stage, you build a solid, continuous evidence base that supports progressing to the next phase and ultimately regulatory approval.

Relying only on animal studies isn’t enough because human safety can differ from animal data, and regulators expect human trial safety data as part of the evidence package. Post-market surveillance comes after a product is already on the market, not as a means to establish safety during development. And immediate market approval without trials bypasses the rigorous, staged evidence required to ensure safety.